VOYAPAK Trademark

Trademark Overview

On Wednesday, August 14, 2013, a trademark application was filed for VOYAPAK with the United States Patent and Trademark Office. The USPTO has given the VOYAPAK trademark a serial number of 86037636. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, December 28, 2015. This trademark is owned by PaxVax, Inc.. The VOYAPAK trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic system, respiratory system, and central nervous system; vaccines
voyapak

General Information

Serial Number86037636
Word MarkVOYAPAK
Filing DateWednesday, August 14, 2013
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, December 28, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 1, 2014

Trademark Statements

Goods and ServicesPharmaceuticals for use in the prevention and treatment of infections conditions, and disorders and diseases related to the gastrointestinal tract, cardiovascular system, metabolic system, respiratory system, and central nervous system; vaccines
Pseudo MarkVOYAPAK; VOYAGE PACK

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, August 22, 2013
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePaxVax, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025
Party NamePaxVax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025

Trademark Events

Event DateEvent Description
Monday, December 28, 2015ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, December 28, 2015ABANDONMENT - NO USE STATEMENT FILED
Tuesday, May 26, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, May 25, 2015EXTENSION 2 GRANTED
Thursday, May 21, 2015EXTENSION 2 FILED
Thursday, May 21, 2015TEAS EXTENSION RECEIVED
Friday, January 16, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 15, 2015EXTENSION 1 GRANTED
Wednesday, November 26, 2014EXTENSION 1 FILED
Thursday, January 15, 2015CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 26, 2014TEAS EXTENSION RECEIVED
Wednesday, August 6, 2014ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, May 27, 2014NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 1, 2014OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 1, 2014PUBLISHED FOR OPPOSITION
Wednesday, March 12, 2014NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, February 26, 2014LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, February 24, 2014ASSIGNED TO LIE
Wednesday, February 5, 2014APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, January 30, 2014TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 30, 2014CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 30, 2014TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, December 9, 2013NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 9, 2013NON-FINAL ACTION E-MAILED
Monday, December 9, 2013NON-FINAL ACTION WRITTEN
Monday, December 2, 2013ASSIGNED TO EXAMINER
Friday, August 23, 2013NOTICE OF PSEUDO MARK E-MAILED
Thursday, August 22, 2013NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, August 17, 2013NEW APPLICATION ENTERED IN TRAM

Related Keywords

voyapak system metabolic cardiovascular respiratory central vaccines nervous tract gastrointestinal infections